QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Airway and systemic inflammation profile in current smokers controls, COPD current smokers and COPD ex-smokers Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009
Restoring corticosteroid sensitivity in COPD and smokers with asthma Source: Annual Congress 2008 - Smokers with asthma versus COPD: differences and similarities Year: 2008
Prulifloxacin in the treatment of acute exacerbations of COPD (AECOPD) in cigarette smokers Source: Annual Congress 2008 - Biomarkers and antibiotic treatment of exacerbations of COPD Year: 2008
Formoterol given either alone or together with tiotropium, reduces the rate of exacerbations in stable COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 430s Year: 2006
Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Enhanced T cell growth from bronchial biopsies of COPD ex-smokers and severe asthmatic subjects compared to COPD current smokers Source: Eur Respir J 2004; 24: Suppl. 48, 39s Year: 2004
Replacing oxytropium with tiotropium significantly improves pulmonary function in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 213s Year: 2006
Frequent exacerbations in ex smokers with COPD are associated with accelerated rate of FEV1 decline Source: Eur Respir J 2005; 26: Suppl. 49, 510s Year: 2005
Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 379s Year: 2004
Asthma control is worse in asthmatic smokers compared to non-smokers with similar lung function Source: Annual Congress 2006 - New investigational approaches to smoking and smoking cessation Year: 2006
Salmeterol 50μg bid significantly reduces moderate-severe exacerbations in patients with all severities of COPD Source: Eur Respir J 2003; 22: Suppl. 45, 68s Year: 2003
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Effects of tiotropium on lung function in current smokers and never smokers with asthma Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Budesonide/formoterol in a single inhaler rapidly improves lung function in adult patients with mild or moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002
Cilomilast decreases exacerbations and maintains lung function in patients with poorly reversible COPD Source: Eur Respir J 2004; 24: Suppl. 48, 88s Year: 2004
Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation-related antibiotic use in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
Systemic interleukin-26 relates to the risk of exacerbations in smokers with COPD and chronic bronchitis Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD Year: 2021